Heidelberg Pharma AG: Heidelberg Pharma AG (HPHA, Frankfurt Stock Exchange), based in Ladenburg, Germany, is a leading biotech company pioneering the use of its ATAC (Antibody Targeted Amanitin Conjugate) platform to develop novel cancer treatments with a unique mode of action effective at specifically killing both inactive and dividing cancers cells and overcoming tumor resistance mechanisms. The platform can be applicable across many cancer types and has a specific genetic biomarker that confers high tumor cell susceptibility to the therapy in many cancer types. Heidelberg Pharma is accelerating development of an internal pipeline of ATACs. Lead product HDP-101, for blood cancer, is expected to start clinical development early 2021. It is also out-licensing the ATAC technology to other companies using the partners’ antibodies to create new ATACs. These partnerships are expected to generate long term income streams and early technology validation.